StockWatch
·
Hospital
Quarterly Result30 Oct 2026, 02:47 pm

Max Healthcare Q2 FY27: revenue +20% YoY, consolidated PAT -16% on tax base (adj. flat)

AI Summary

Max Healthcare's consolidated revenue rose 20.3% YoY to ₹2,569.21 Cr (+8.6% QoQ) in Q2 FY27, while consolidated PAT (profit for the period) came in at ₹414.45 Cr, down 15.6% YoY but up 28.3% QoQ. The YoY profit decline is a base-effect artefact rather than an operating miss: Q2 FY26 tax expense included a one-off ₹79.39 Cr current-tax reversal credit booked on the Crosslay Remedies (formerly Jaypee Healthcare) merger, which lifted that quarter's reported PAT to ₹491.30 Cr. Stripping that one-off out, adjusted YoY PAT growth is roughly flat (~+0.6%), a materially different read from the -15.6% headline. Operating margin actually expanded both YoY and QoQ — OPM rose to 27.69% from 26.93% a year ago and 25.29% last quarter — so the underlying business got more profitable at the EBITDA line even as reported net profit margin fell to 15.88% from 22.66% YoY (13.42% in Q1 FY27), the gap being almost entirely the tax-line swing described above, not cost pressure. This runs counter to the prior concall's caution that near-term EBITDA would stay muted as new beds at Max Smart, Nanavati and Sector-56 Gurgaon absorb fixed costs before ramping — margins held up better than that framing implied, even as the company confirmed network-wide capacity utilisation stayed high at >75% across 6,100+ beds. Part of the topline growth is inorganic: Kalinga Hospital (acquired, 58.28% then raised to 66.34% via rights issue, consolidated from May 18, 2026) and Yerawada Properties (YPPL, from June 30, 2026) are in the Q2 FY27 base but were absent or partial in the year-ago quarter, so like-for-like organic growth is lower than the 20.3% headline — the filing does not break out the split. Alongside results, the Board approved fresh capex of ~₹93 Cr for Max Super Speciality Hospital Noida (+85 beds) and ~₹97 Cr for Vaishali (+60 beds), and revised the cost of the 525-bed Sector-56 Gurgaon greenfield project upward to ~₹1,143 Cr with completion pushed out to April 2027 (from the original schedule), citing façade, atrium and interior fit-out changes. No separate management press release was available to cross-check tone against the numbers, and no broker consensus for this specific quarter was found in search (results were announced same-day), so vs-street is left unresolved. Standalone (holding-company-only, ex most hospital subsidiaries) PAT was ₹168.33 Cr on revenue of ₹841.97 Cr, +14.3% YoY — consolidated remains the primary read since the bulk of hospital operations sit in subsidiaries and silos. Going into Q3, the key markers are whether CGHS recoveries stay on track for management's ₹140 Cr FY27 target (not disclosed this quarter), how fast the new Noida/Vaishali/Gurgaon beds ramp given the extended Gurgaon timeline, and the outcome of the Kalinga Hospital NCLT hearing (adjourned again, next date pending), which sits with a subsidiary and is not yet material to Group financials per the auditor's note.

Key Highlights

  • Consolidated revenue ₹2,569.21 Cr, +20.3% YoY, +8.6% QoQ
  • Consolidated PAT ₹414.45 Cr, -15.6% YoY (adjusted ~+0.6% YoY ex a ₹79.39 Cr one-off prior-year tax credit); +28.3% QoQ
  • OPM expanded to 27.69% (vs 26.93% YoY, 25.29% QoQ); NPM 15.88% (vs 22.66% YoY, 13.42% QoQ) — YoY NPM fall is tax-driven, not operational
  • Board approved ~₹93 Cr capex for MSSH Noida (+85 beds) and ~₹97 Cr for MSSH Vaishali (+60 beds); Sector-56 Gurgaon (525 beds) cost revised to ~₹1,143 Cr, completion pushed to April 2027
  • Network capacity utilisation >75% across 6,100+ beds in Q2 FY27
  • Standalone PAT ₹168.33 Cr on revenue ₹841.97 Cr, +14.3% YoY
  • Dr. Dharmender Kumar appointed Director & Chief-Public Affairs effective Nov 1, 2026; 95,000 fresh ESOP options granted and 66,462 shares allotted under the existing scheme this quarter